Answers are grounded in this paper and cite their sources.
In this systematic meta-analysis, anti-PD1/PD-L1 mAbs were associated with a greater overall response rate. Patients with melanoma and those managed in the first line setting seem to have an additional benefit with anti-PD1/PD-L1 mAbs.
No takes yet. Share an insight, caveat, or question.
Carretero-González et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: